API: Entry Inhibitor — gp120–CD4 Interface Blocker
Profile Code: SCF-API-HIV-ENTRY-gp120-001
Program: SCF-Fibonacci HIV Therapy Program
Therapeutic Focus: HIV/AIDS
Fibonacci Position: Step 1 — Viral Entry (Primary Gate)
SCF Role Intent: Preventative / Resistance-Preventive
1. Phase Objective
Per the SCF complete workflow, Phase 1 is used to retrieve and prioritize relevant traditional bioactive sources, screen for documented therapeutic roles, and map those roles to modern disease states or molecular pathways. For this HIV entry inhibitor, the Phase 1 objective is adapted as follows:
To identify ethnopharmacologic, natural-product, and biomedical translation sources that can inform a virus-surface-targeted entry inhibitor directed at the gp120–CD4 interface, while preserving the profile’s non-negotiable constraint of blocking attachment without triggering gp120 activation.
2. Phase 1 Framing Logic for This API
The supplied API profile already defines:
- the target node as the gp120 CD4-binding interface,
- the desired functional outcome as prevention of stable gp120–CD4 engagement,
- the key design distinction as non-activating conformational restraint,
- the SCF role as preventative / resistance-preventive,
- the therapeutic positioning as adjunctive to standard ART.
Accordingly, Phase 1 does not begin with broad anti-HIV folklore screening alone. It begins with target-constrained source scouting, meaning all candidate source domains are filtered through five SCF discovery gates:
Discovery Gate | Phase 1 Requirement for This API |
Target specificity | Candidate source must plausibly yield a scaffold capable of viral-envelope surface engagement rather than host CD4 antagonism |
Mechanistic fidelity | Source logic must support steric masking, conformational locking, or extracellular attachment interference |
Resistance prevention | Preference for sources associated with multi-contact surface chemistry or conserved-interface recognition |
PK relevance | Preference for source chemotypes amenable to mucosal, lymphoid, or long-acting extracellular exposure |
Safety thesis | Source must support virus-restricted action with low probability of host immune suppression |
This is consistent with the SCF Principles emphasis on targeted drug action, PK optimization, metabolic efficiency, resistance prevention, and safety profile optimization.
3. Phase 1 Core Tasks Applied to SCF-API-HIV-ENTRY-gp120-001
The SCF workflow defines three Phase 1 tasks: collect ethnobotanical/traditional medicine data, screen documented clinical effects and therapeutic roles, and map usage to modern disease states or molecular pathways. Applied here, those tasks become:
3.1 Task 1.1 — Source Domain Collection
A. Biomedical Translation Source
Primary source class for this API is not a crude antiviral herb claim alone, but any natural or ethnomedical source that can be reverse-translated into one of three mechanistic classes:
- surface-shielding ligands,
- conformational-locking ligands,
- peptide-mimetic docking blockers.
B. Ethnobioprospecting Source Classes
Using the SCF ethnomedical reference systems, the most relevant source domains for this target class are those with longstanding use in infectious, mucosal, inflammatory, or “protective barrier” contexts rather than systemic immunosuppression alone. Suitable scouting domains include:
- Traditional Chinese Medicine,
- Ayurveda,
- Unani,
- Amazonian medicine,
- Yoruba/Sub-Saharan ethnomedicine,
- Kampo and related East Asian derivative systems.
C. Inclusion Logic
Because this API acts at viral entry, Phase 1 source collection prioritizes traditions associated with:
- mucosal protection,
- barrier fortification,
- antimicrobial/antiviral topical or systemic use,
- lectin-like or polyphenolic surface-binding chemistry,
- structured peptide or cyclic-peptide natural product space,
- glycan-interacting phytochemistries.
3.2 Task 1.2 — Traditional Therapeutic Role Screening
Phase 1 screening is limited to source traditions whose historical use can be reverse-mapped into one or more of the following SCF-compatible therapeutic functions:
Traditional/Empirical Role | SCF Translation Relevance |
Protective barrier / anti-invasion | Viral attachment interference |
Anti-infective surface defense | Extracellular virion neutralization logic |
Mucosal fortification | Exposure-site pharmacology relevance |
Inflammation moderation without immune collapse | Safety harmonization for adjunctive ART use |
Tissue-preserving anti-inflammatory action | Reservoir-seeding mitigation support |
Multi-component protective formulas | Resistance-barrier scaffolding logic |
This is aligned with the API Discovery Profile requirement to use ethnobioprospecting-based analysis, geographically and culturally aligned to source origin, and to construct a structured FDA-aligned preclinical profile from those translated sources.
3.3 Task 1.3 — Mapping to Modern Pathway Biology
For this profile, the traditional-use-to-modern-pathway mapping is constrained to entry biology:
Traditional Function Theme | Modern Molecular Translation |
Anti-adhesion / anti-attachment | gp120 surface masking; interference with CD4 docking geometry |
“Closing,” “cooling,” or stabilizing formulas | Conformational locking of envelope glycoprotein in non-productive state |
Barrier/mucosa defenders | Front-end extracellular exposure optimization at mucosal and lymphoid interfaces |
Broad anti-infective protection | Entry-stage suppression before reverse transcription |
Protective combinations | Orthogonality with RT and integrase inhibitors |
The target is therefore not generalized antiviral suppression, but a pre-replicative interruption node positioned before co-receptor exposure, fusion, reverse transcription, and reservoir seeding, matching the supplied SCF logic for the profile.
4. Phase 1 Candidate Source-Hypothesis Matrix
This section is a scouting hypothesis matrix only. It is not a claim that any named source is already validated for gp120 blockade.
Source Domain | Ethnomedical Logic | Candidate Chemical Logic | Phase 1 Relevance to gp120–CD4 Blockade | Initial SCF Disposition |
TCM mucosal/protective botanicals | Exterior protection, toxin-clearing, barrier support | Polyphenols, tannins, saponins, glycoside-rich scaffolds | May support surface-binding or glycan-interference hypotheses | High-interest scouting pool |
Ayurveda rasayana + anti-infective botanicals | Tissue protection, host resilience, pathogen burden reduction | Flavonoids, triterpenoids, alkaloids | Useful for conformational-stability or adjunct safety logic | High-interest scouting pool |
Unani anti-infective materia medica | Humoral correction and infection defense | Quinones, phenolics, volatile fractions | Relevant for extracellular viral-surface interaction hypotheses | Moderate-to-high interest |
Amazonian protective botanicals | Plant-spirit “defense” medicines often correspond to strong bioactive phytochemistry | Alkaloids, cyclic peptides, terpenoids | Valuable for unusual scaffolds and peptide-mimetic inspiration | High novelty interest |
African ethnomedicinal anti-infectives | Broad infection-defense and mucosal application traditions | Polyphenolics, terpenes, limonoids, alkaloids | Good source diversity for conserved-surface binding chemotypes | High-interest scouting pool |
Marine/natural peptide analog space | Not strictly ethnobotanical, but valid translational natural-product space | Cyclic peptides, depsipeptides, peptidomimetics | Strong relevance for steric blockade and conformational lock designs | Priority adjunct scouting pool |
5. Preliminary Phase 1 Source Selection Criteria
A source advances from Phase 1 only if it satisfies all of the following:
Criterion | Advancement Threshold |
Mechanistic plausibility | Can be reverse-engineered into gp120-surface masking, conformational locking, or peptide-mimetic blockade |
Host-sparing profile | No primary dependence on CD4 depletion, immune suppression, or broad host-membrane toxicity |
Conserved-interface relevance | Chemistry likely to engage conserved viral-surface determinants rather than hypervariable loops alone |
Developability | Feasible transition into small molecule, peptidomimetic, or semisynthetic lead scaffold |
Combination compatibility | Plausibly orthogonal to RT/IN inhibitor classes |
Translational tractability | Amenable to later PK engineering for mucosal/lymphoid exposure |
6. SCF Disease-Origin and Pathway Alignment
The SCF research workflow places early discovery within disease-origin modeling, pathogenesis mapping, mechanistic reverse engineering, and source-to-biomedical translation. For this HIV entry program, Phase 1 maps as follows:
SCF Research Section | Application to This API |
Disease-Origin Modeling | Viral-origin pathology with entry-stage permission node as earliest actionable fault |
Pathogenesis Mapping | Prevent gp120-mediated initiation of downstream viral cascade |
Mechanistic Reverse Engineering | Translate natural-source chemistry into attachment-blockade logic |
Source-to-Biomedical Translation | Convert ethnomedical protective functions into entry-inhibitor scaffold hypotheses |
Safety & Compatibility Modeling | Exclude source classes with host receptor suppression risk |
7. Phase 1 Working Hypothesis
A successful Phase 1 outcome for SCF-API-HIV-ENTRY-gp120-001 will identify one or more source-informed scaffold families capable of one of the following:
- masking conserved gp120 residues required for CD4 docking,
- stabilizing gp120 in a closed, non-productive conformation,
- generating a short structured peptidomimetic that sterically blocks productive receptor engagement,
while maintaining the profile’s essential safety requirement of avoiding CD4 down-modulation or immune suppression. This directly preserves the API’s canonical preventative logic: stop entry before replication, mutation expansion, and reservoir seeding begin.
8. Phase 1 Deliverables
Deliverable Code | Deliverable Name | Status |
P1-D01 | Ethnopharmacological Source Universe Map | Initiated |
P1-D02 | gp120 Entry-Constraint Discovery Filter | Completed in principle |
P1-D03 | Candidate Source-Hypothesis Matrix | Completed |
P1-D04 | Source-to-Mechanism Translation Table | Completed |
P1-D05 | Phase 1 Advancement Criteria | Completed |
P1-D06 | Phase 2 Extraction Readiness Recommendation | Completed |
9. Phase 1 Go / No-Go Decision
Go
Advance to Phase 2 for any source class that supports:
- non-host-directed viral surface engagement,
- plausible conserved-interface recognition,
- conformational lock or steric-block mechanism,
- later conversion into medicinal-chemistry or peptidomimetic lead space.
No-Go
Eliminate any source class whose discovery logic depends on:
- host CD4 interference,
- generalized membrane disruption,
- nonspecific cytotoxic antiviral effects,
- purely post-entry antiviral activity inconsistent with Step 1 positioning.
10. Phase 2 Readiness Statement
Phase 1 is now initiated and framed for SCF-API-HIV-ENTRY-gp120-001. The next phase should proceed as Bioactive Compound Extraction & SCF Analysis, where candidate source classes are converted into concrete scaffold hypotheses, MoA/MeA assignments, SCF role assignments, and five-axis SCF analysis. That sequencing matches the SCF complete workflow and the API Discovery Profile structure.
MASTER DOCUMENT REGISTRY INDEX
- SCF-API-HIV-ENTRY-gp120-001
- SCF-FIB-ENTRY-GATE
- SCF-RESERVOIR-PREVENTION
- SCF-P1-HIV-ENTRY-SCOUT-001
- SCF-PHASE1-ETHNOPHARM-SCOUTING-HIV
- SCF-RD-HIV-ENTRY-FIB1
Reply with Phase 2 and I will continue with Bioactive Compound Extraction & SCF Analysis.